← 返回前沿论文

免疫细胞表型与胶质瘤风险的介导孟德尔随机化分析:揭示脑脊液代谢物的调控作用

英文原题:Mediation Mendelian randomization analysis of immune cell phenotypes and glioma risk: unveiling the regulation of cerebrospinal fluid metabolites.

查看英文原题

Mediation Mendelian randomization analysis of immune cell phenotypes and glioma risk: unveiling the regulation of cerebrospinal fluid metabolites.

PubMed 2025/05/09(内容时间) Discov Oncol Q3 · IF 2.8(JCR 2025)

研究概要

本研究识别出特定免疫细胞表型直接影响胶质瘤风险,并通过脑脊液代谢物间接调控该风险。IgD(+) CD24(-) B细胞上的CD19被确定为风险因素,而单核细胞上的CD11c具有保护作用。7-hoca和甘油磷酸肌醇等代谢物发挥关键中介作用。这些发现增进了我们对胶质瘤病理生理学的理解,并提示免疫调节和代谢干预可能是具有前景的治疗策略。

研究思路结论见上方概要

胶质瘤,尤其是多形性胶质母细胞瘤(GBM),是成人中最常见的原发性中枢神经系统肿瘤,由于其高度异质性和侵袭性,治疗极为困难。尽管分子诊断和个体化治疗取得了进展,预后仍然很差。免疫系统在胶质瘤进展中发挥关键作用。本研究采用中介孟德尔随机化分析,探讨免疫细胞表型、脑脊液代谢物与胶质瘤之间的关系,旨在揭示肿瘤进展和免疫逃逸的潜在机制。

本研究采用了IVW、MR Egger、Simple mode、Weighted median和Weighted mode等多种分析方法,其中以IVW结果为主要依据。我们评估了异质性和多效性,并使用留一法分析确定敏感性,确保结果的稳定性和可靠性。研究了脑脊液代谢物的潜在中介效应,以探索免疫细胞功能与胶质瘤之间的潜在机制。本研究中使用的免疫细胞、脑脊液代谢物和胶质瘤的GWAS数据均来源于公共数据库。

我们确定了九种胶质瘤风险免疫细胞表型(例如IgD(+) CD24(-)上的CD19),以及十种保护性免疫细胞表型(例如单核细胞上的CD11c)。中介分析显示,7-alpha-hydroxy-3-oxo-4-cholestenoate (7-hoca)水平(MP = - 14.6%)和Palmitoyl dihydrosphingomyelin (d18:0/16:0)水平(MP = 7.9%)部分中介了CD39(+)静息Treg细胞上的CD3与胶质瘤之间的关系。此外,7-hoca水平(MP = - 12.3%)和Phenyllactate (pla)水平(MP = 4.12%)部分中介了NKT细胞上的FSC-A与胶质瘤之间的关联。进一步地,Glycerophosphoinositol水平(MP = - 12.1%)和Orotate水平(MP = - 11.4%)部分中介了Granulocyte adenylyl cyclase (Granulocyte AC)与胶质瘤之间的关系。

展开英文摘要原文

BACKGROUND AND OBJECTIVE: Gliomas, particularly glioblastoma multiforme (GBM), are the most common primary central nervous system tumors in adults and are notoriously difficult to treat due to their high heterogeneity and invasiveness. Despite advances in molecular diagnostics and personalized therapies, prognosis remains poor. The immune system plays a critical role in glioma progression. This study employed mediation Mendelian randomization analysis to explore the relationships between immune cell phenotypes, cerebrospinal fluid metabolites, and glioma, aiming to uncover potential mechanisms of tumor progression and immune evasion. METHOD: In this study, we employed several analytical methods including IVW, MR Egger, Simple mode, Weighted median, and Weighted mode, with IVW results being considered the primary basis. We assessed heterogeneity and pleiotropy, and used leave-one-out analysis to determine sensitivity, ensuring the stability and reliability of the results. The potential mediating effects of cerebrospinal fluid metabolites were investigated to explore the underlying mechanisms linking immune cell function and glioma. The GWAS data for immune cells, cerebrospinal fluid metabolites, and glioma used in this study were sourced from public databases. RESULT: We identified nine risk immune cell phenotypes for glioma (such as CD19 on IgD( +) CD24(-)), and ten protective immune cell phenotypes (such as CD11c on monocytes). Mediation analysis revealed that levels of 7-alpha-hydroxy-3-oxo-4-cholestenoate (7-hoca) (MP = - 14.6%) and Palmitoyl dihydrosphingomyelin (d18:0/16:0) (MP = 7.9%) partially mediated the relationship between CD3 on CD39( +) resting Treg cells and glioma. Additionally, 7-hoca levels (MP = - 12.3%) and Phenyllactate (pla) levels (MP = 4.12%) partially mediated the association between FSC-A on NKT cells and glioma. Furthermore, Glycerophosphoinositol levels (MP = - 12.1%) and Orotate levels (MP = - 11.4%) partially mediated the relationship between Granulocyte adenylyl cyclase (Granulocyte AC) and glioma. CONCLUSION: This study identified that specific immune cell phenotypes directly influence glioma risk and indirectly modulate this risk through cerebrospinal fluid metabolites. CD19 on IgD( +) CD24(-) B cells were identified as risk factors, while CD11c on monocytes were protective. Metabolites like 7-hoca and glycerophosphoinositol play key mediating roles. These findings enhance our understanding of glioma pathophysiology and suggest that immune modulation and metabolic intervention may be promising therapeutic strategies.

论文信息

作者
Zhao S、Jiang J、Zhang J、Jin X
第一作者单位
Emergency Center, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuchang, Wuhan, 430071, Hubei, China.China
通讯作者单位
Emergency Center, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuchang, Wuhan, 430071, Hubei, China. redjin@whu.edu.cn.China
期刊
Discover oncology2025 May 9
原文标识
PubMed 40343558 · DOI 10.1007/s12672-025-02499-y